Detalhe da pesquisa
1.
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
Rheumatology (Oxford)
; 61(11): 4263-4272, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179569
2.
Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.
Vaccines (Basel)
; 11(4)2023 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37112731